Freeing humanity from respiratory viruses: building Leyden Labs
21 May 2026 - Utrecht
In this session, Dennis will share the journey of building Leyden Labs, a biotech company focused on protecting humanity from respiratory viruses. He will reflect on key lessons from starting and scaling a biotech venture - from shaping a clear scientific vision and securing investment to building a high-performing team, navigating partnerships, and advancing drug development. The talk offers a practical and candid perspective on the challenges and opportunities of building a biotech company in a rapidly evolving landscape.
About Leyden Labs
Leyden Labs is a Dutch biotechnology company employing a novel, non-vaccine approach to fight back against the threat of respiratory viruses. The goal is to provide unprecedented breadth of protection against respiratory viruses right in the palm of the hand of those who need protection the most. The company's product candidates are nasal sprays that are developed following the principles that they must provide protection right at the gate of viral entry (in the airway) and deliver superior breadth of protection. These product candidates offer an opportunity to overcome major limitations of existing vaccine-based protection.
In this session, Dennis will share the journey of building Leyden Labs, a biotech company focused on protecting humanity from respiratory viruses. He will reflect on key lessons from starting and scaling a biotech venture - from shaping a clear scientific vision and securing investment to building a high-performing team, navigating partnerships, and advancing drug development. The talk offers a practical and candid perspective on the challenges and opportunities of building a biotech company in a rapidly evolving landscape.
About Leyden Labs
Leyden Labs is a Dutch biotechnology company employing a novel, non-vaccine approach to fight back against the threat of respiratory viruses. The goal is to provide unprecedented breadth of protection against respiratory viruses right in the palm of the hand of those who need protection the most. The company's product candidates are nasal sprays that are developed following the principles that they must provide protection right at the gate of viral entry (in the airway) and deliver superior breadth of protection. These product candidates offer an opportunity to overcome major limitations of existing vaccine-based protection.
Dennis de Vlaam | Director of Business Development | Leyden Labs
Dennis has a background in Business Administration and over a decade of experience building and scaling early-stage companies across various industries. He served as CEO of Reunion Therapeutics, a company developing treatments for inflammatory diseases, and later joined Leyden Labs at its inception in 2020 as its first employee. There, he was involved in building the company’s business operations from the ground up, leading initiatives across strategic partnerships, licensing, and organizational development. Dennis currently leads business development at Leyden Labs, where he is responsible for licensing technologies, and supporting the company’s growth through forging strategic partnerships.
Dennis de Vlaam | Director of Business Development | Leyden Labs
Dennis has a background in Business Administration and over a decade of experience building and scaling early-stage companies across various industries. He served as CEO of Reunion Therapeutics, a company developing treatments for inflammatory diseases, and later joined Leyden Labs at its inception in 2020 as its first employee. There, he was involved in building the company’s business operations from the ground up, leading initiatives across strategic partnerships, licensing, and organizational development. Dennis currently leads business development at Leyden Labs, where he is responsible for licensing technologies, and supporting the company’s growth through forging strategic partnerships.
| For job seekers | For employers | Join BCF Career Event |
| | SUBSCRIBE TO OUR NEWSLETTER | |
| Powered by: Hyphen Projects Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 |
© Copyright 2025 by Hyphen Projects